# EDGAR Filing Document

**Accession Number:** 0001829635
**File Stem:** 0001104659-23-017969
**Filing Date:** 2023-2
**Character Count:** 10436
**Document Hash:** 74650e97872bd32151bf41ee288f5925
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-017969.hdr.sgml**: 20230210

**ACCESSION NUMBER**: 0001104659-23-017969

**CONFORMED SUBMISSION TYPE**: SC 13G/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230210

**DATE AS OF CHANGE**: 20230210

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Transcode Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001829635
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 811065054
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92695
- **FILM NUMBER:** 23608588

**BUSINESS ADDRESS:**
- **STREET 1:** 6 LIBERTY SQUARE
- **STREET 2:** #2382
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
- **BUSINESS PHONE:** 857-301-6857

**MAIL ADDRESS:**
- **STREET 1:** 6 LIBERTY SQUARE
- **STREET 2:** #2382
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Medarova Zdravka
- **CENTRAL INDEX KEY:** 0001855758

**FILING VALUES:**
- **FORM TYPE:** SC 13G/A

**MAIL ADDRESS:**
- **STREET 1:** C/O TRANSCODE THERAPEUTICS, INC.
- **STREET 2:** 6 LIBERTY SQUARE, #2382
- **CITY:** BOSTON
- **STATE:** MA
- **ZIP:** 02109

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13G**

**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**(Amendment No. 1)\***

**TransCode Therapeutics, Inc.**

**(Name of Issuer)**

**<u>Common Stock, $0.0001 par value per share</u>**

**(Title of Class of Securities)**

**<u>89357L105</u>**

**(CUSIP Number)**

**<u>December 31, 2022</u>**

**(Date of Event Which Requires Filing of this Statement)**

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

◻ Rule 13d-1(b)

◻ Rule 13d-1(c)

🗹 Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

---

| | | |
|:---|:---|:---|
| **CUSIP No. 89357L105** | **SCHEDULE 13G** | **Page 2 of 5 Pages** |

---

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;1. | NAMES OF REPORTING PERSONS<br>**Zdravka Medarova** | NAMES OF REPORTING PERSONS<br>**Zdravka Medarova** | NAMES OF REPORTING PERSONS<br>**Zdravka Medarova** |
| &nbsp;&nbsp;&nbsp;&nbsp;2. | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻ (b) ◻ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻ (b) ◻ | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP<br> (a) ◻ (b) ◻ |
| &nbsp;&nbsp;&nbsp;&nbsp;3. | SEC USE ONLY | SEC USE ONLY | SEC USE ONLY |
| &nbsp;&nbsp;&nbsp;&nbsp;4. | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States of America | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States of America | CITIZENSHIP OR PLACE OF ORGANIZATION<br>United States of America |
| &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | &nbsp;&nbsp; NUMBER OF<br> SHARES<br> BENEFICIALLY<br> OWNED BY<br> EACH<br> REPORTING<br> PERSON<br> WITH | 5. | SOLE VOTING POWER<br>1,660,739 (1) |
|  |  | 6. | SHARED VOTING POWER<br>0 |
|  |  | 7. | SOLE DISPOSITIVE POWER<br>1,660,739 (1) |
|  |  | 8. | SHARED DISPOSITIVE POWER<br>0 |
| &nbsp;&nbsp;&nbsp;&nbsp;9. | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>1,660,739 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>1,660,739 (1) | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON<br>1,660,739 (1) |
| 10. | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻ | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻ | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ◻ |
| 11. | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9<br>12.7% (2) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9<br>12.7% (2) | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9<br>12.7% (2) |
| 12. | TYPE OF REPORTING PERSON<br>IN | TYPE OF REPORTING PERSON<br>IN | TYPE OF REPORTING PERSON<br>IN |

---

(1) Consists of (i) 1,552,787 shares of Common Stock held directly by the Reporting Person and (ii) 107,952 shares issuable to the Reporting Person upon exercise of stock options exercisable within 60 days of December 31, 2022.

(2) Percentage ownership is calculated based on (i) 12,977,234 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022, plus (ii) 107,952 shares of Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2022, which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

---

| | | |
|:---|:---|:---|
| **CUSIP No. 89357L105** | **SCHEDULE 13G** | **Page 3 of 5 Pages** |

---

---

| | | |
|:---|:---|:---|
| **Item 1.** |  | **Issuer** |
|  | (a) | Name of Issuer: |
|  |  | TransCode Therapeutics, Inc. (the "**<u>Issuer</u>**") |
|  | (b) | Address of Issuer's Principal Executive Offices: |
|  |  | 6 Liberty Square, #2382 <br> Boston, MA 02109 |
| **Item 2.** |  | **Filing Person** |
|  | (a) – (c) | Name of Persons Filing; Address; Citizenship: <br>This statement on Schedule 13G is filed by Zdravka Medarova (the "Reporting Person"), a citizen of the United States of America. The principal business address of the Reporting Person is c/o TransCode Therapeutics, Inc., 6 Liberty Square, #2382, Boston, MA 02109. |
|  | (d) | Title of Class of Securities: |
|  |  | Common Stock, par value $0.0001 per share |
|  | (e) | CUSIP Number: |
|  |  | 89357L105 |
| **Item 3.** | **If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:** | **If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:** |
|  | (a) | Broker or dealer registered under Section 15 of the Act; |
|  | (b) | Bank as defined in Section 3(a)(6) of the Act; |
|  | (c) | Insurance company as defined in Section 3(a)(19) of the Act; |
|  | (d) | Investment company registered under Section 8 of the Investment Company Act of 1940; |
|  | (e) | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); |
|  | (f) | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); |
|  | (g) | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); |
|  | (h) | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
|  | (i) | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940; |
|  | (j) | A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J); |
|  | (k) | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: |
|  |  | If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: |

---

---

| | | |
|:---|:---|:---|
| **CUSIP No. 89357L105** | **SCHEDULE 13G** | **Page 4 of 5 Pages** |

---

---

| | |
|:---|:---|
| **Item 4.** | **Ownership.** |
| (a) and (b) | Amount beneficially owned; Percent of class: |
|  | As of December 31, 2022, the Reporting Person beneficially owned an aggregate of 1,660,739 shares of Common Stock, which consisted of (i) 1,552,787 shares of Common Stock held directly by the Reporting Person and (ii) 107,952 shares of Common Stock issuable to the Reporting Person upon exercise of stock options exercisable within 60 days of December 31, 2022, representing approximately 12.7% of the outstanding shares of Common Stock. The percent of class was calculated based on (i) 12,977,234 shares of Common Stock outstanding, as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 14, 2022, plus (ii) 107,952 shares of Common Stock underlying stock options held by the Reporting Person that are exercisable within 60 days of December 31, 2022, which are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i). |
| (c) | Number of shares as to which such person has: |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Number of Shares of Common Stock** | **Number of Shares of Common Stock** | **Number of Shares of Common Stock** | **Number of Shares of Common Stock** |
| **Reporting Person** | (i) | (ii) | (iii) | (iv) |
| Zdravka Medarova | 1660739 | 0 | 1660739 | 0 |

---

(i) Sole power to vote or direct the vote

(ii) Shared power to vote or to direct the vote

(iii) Sole power to dispose or to direct the disposition of

(iv) Shared power to dispose or to direct the disposition of

---

| | |
|:---|:---|
| **Item 5.** | **Ownership of Five Percent or Less of a Class.**<br>Not applicable. |
| **Item 6.** | **Ownership of More than Five Percent on Behalf of Another Person.**<br>Not applicable. |
| **Item 7.** | **Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.**<br>Not applicable. |
| **Item 8.** | **Identification and Classification of Members of the Group.**<br>Not applicable. |
| **Item 9.** | **Notice of Dissolution of Group.**<br>Not applicable. |
| **Item 10.** | **Certification.**<br>Not applicable. |

---

---

| | | |
|:---|:---|:---|
| **CUSIP No. 89357L105** | **SCHEDULE 13G** | **Page 5 of 5 Pages** |

---

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 10, 2023

---

| |
|:---|
| /s/ Zdravka Medarova |
| **ZDRAVKA MEDAROVA** |

---